104 related articles for article (PubMed ID: 2784122)
1. A phase 1a clinical trial of LYM-1 monoclonal antibody serotherapy in patients with refractory B cell malignancies.
Hu E; Epstein AL; Naeve GS; Gill I; Martin S; Sherrod A; Nichols P; Chen D; Mazumder A; Levine AM
Hematol Oncol; 1989; 7(2):155-66. PubMed ID: 2784122
[TBL] [Abstract][Full Text] [Related]
2. Antilymphoma effects of anti-HLA-DR and CD20 monoclonal antibodies (Lym-1 and Rituximab) on human lymphoma cells.
Liu C; DeNardo G; Tobin E; DeNardo S
Cancer Biother Radiopharm; 2004 Oct; 19(5):545-61. PubMed ID: 15650447
[TBL] [Abstract][Full Text] [Related]
3. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential.
Epstein AL; Marder RJ; Winter JN; Stathopoulos E; Chen FM; Parker JW; Taylor CR
Cancer Res; 1987 Feb; 47(3):830-40. PubMed ID: 3542194
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas.
Press OW; Appelbaum F; Ledbetter JA; Martin PJ; Zarling J; Kidd P; Thomas ED
Blood; 1987 Feb; 69(2):584-91. PubMed ID: 3492224
[TBL] [Abstract][Full Text] [Related]
5. Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies.
DeNardo SJ; DeNardo GL; O'Grady LF; Hu E; Sytsma VM; Mills SL; Levy NB; Macey DJ; Miller CH; Epstein AL
Int J Cancer Suppl; 1988; 3():96-101. PubMed ID: 3209308
[TBL] [Abstract][Full Text] [Related]
6. Antibody-dependent, cell-mediated cytotoxicity by an anti-class II murine monoclonal antibody: effects of recombinant interleukin 2 on human effector cell lysis of human B-cell tumors.
Biddle WC; Pancook J; Goldrosen M; Han T; Foon KA; Vaickus L
Cancer Res; 1990 May; 50(10):2991-6. PubMed ID: 2334902
[TBL] [Abstract][Full Text] [Related]
7. Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors.
Zhang N; Khawli LA; Hu P; Epstein AL
Cancer Biother Radiopharm; 2007 Jun; 22(3):342-56. PubMed ID: 17651040
[TBL] [Abstract][Full Text] [Related]
8. Direct antilymphoma effects on human lymphoma cells of monotherapy and combination therapy with CD20 and HLA-DR antibodies and 90Y-labeled HLA-DR antibodies.
DeNardo GL; Tobin E; Chan K; Bradt BM; DeNardo SJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7075s-7079s. PubMed ID: 16203805
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of nonconjugated murine Lym-2 and human-mouse chimeric CLL-1 monoclonal antibodies against various human lymphoma cell lines in vitro and in vivo.
Funakoshi S; Hirano A; Beckwith M; Asai O; Jorgensen G; Tian Z; Hornick JL; Hu P; Khawli LA; Epstein AL; Longo DL; Murphy WJ
Blood; 1997 Oct; 90(8):3160-6. PubMed ID: 9376598
[TBL] [Abstract][Full Text] [Related]
10. Internalization and shedding of Lym-1 monoclonal antibody following interaction with surface antigens of a cultured human B cell lymphoma.
Wang BS; Kelley KA; Lumanglas AL; Zimmer AM; Durr FE
Cell Immunol; 1989 Oct; 123(2):283-93. PubMed ID: 2790963
[TBL] [Abstract][Full Text] [Related]
11. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10.
Rose LM; Gunasekera AH; DeNardo SJ; DeNardo GL; Meares CF
Cancer Immunol Immunother; 1996 Sep; 43(1):26-30. PubMed ID: 8917632
[TBL] [Abstract][Full Text] [Related]
12. 67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.
O'Donnell RT; DeNardo GL; Kukis DL; Lamborn KR; Shen S; Yuan A; Goldstein DS; Mirick GR; DeNardo SJ
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3330s-3336s. PubMed ID: 10541382
[TBL] [Abstract][Full Text] [Related]
13. [I-131-LYM-1 MoAb radioimmunotherapy and LYM-1 MoAb immunotherapy in implanted nude mice model].
Chen KY
Zhonghua Zhong Liu Za Zhi; 1988 Nov; 10(6):424-6. PubMed ID: 3266932
[TBL] [Abstract][Full Text] [Related]
14. Fully human antibody exhibits pan-human leukocyte antigen-DR recognition and high in vitro/vivo efficacy against human leukocyte antigen-DR-positive lymphomas.
Tawara T; Hasegawa K; Sugiura Y; Tahara T; Ishida I; Kataoka S
Cancer Sci; 2007 Jun; 98(6):921-8. PubMed ID: 17428256
[TBL] [Abstract][Full Text] [Related]
15. A human-mouse chimeric Lym-1 monoclonal antibody with specificity for human lymphomas expressed in a baculovirus system.
Hu P; Glasky MS; Yun A; Alauddin MM; Hornick JL; Khawli LA; Epstein AL
Hum Antibodies Hybridomas; 1995; 6(2):57-67. PubMed ID: 7492752
[TBL] [Abstract][Full Text] [Related]
16. Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study.
Schweighofer CD; Tuchscherer A; Sperka S; Meyer T; Rattel B; Stein S; Ismail S; Elter T; Staib P; Reiser M; Hallek M
Cancer Immunol Immunother; 2012 Dec; 61(12):2367-73. PubMed ID: 23090290
[TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody T101 in T cell malignancies: a clinical, pharmacokinetic, and immunologic correlation.
Bertram JH; Gill PS; Levine AM; Boquiren D; Hoffman FM; Meyer P; Mitchell MS
Blood; 1986 Sep; 68(3):752-61. PubMed ID: 3488778
[TBL] [Abstract][Full Text] [Related]
18. Direct antilymphoma activity of novel, first-generation "antibody mimics" that bind HLA-DR10-positive non-Hodgkin's lymphoma cells.
West J; Perkins J; Hok S; Balhorn R; Lightstone FC; Cosman M; DeNardo SJ; DeNardo GL
Cancer Biother Radiopharm; 2006 Dec; 21(6):645-54. PubMed ID: 17257080
[TBL] [Abstract][Full Text] [Related]
19. Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.
Vlasveld LT; Hekman A; Vyth-Dreese FA; Melief CJ; Sein JJ; Voordouw AC; Dellemijn TA; Rankin EM
Cancer Immunol Immunother; 1995 Jan; 40(1):37-47. PubMed ID: 7530170
[TBL] [Abstract][Full Text] [Related]
20. Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.
Schillaci O; DeNardo GL; DeNardo SJ; Goldstein DS; Kroger LA; O'Donnell RT; Lamborn KR
Cancer Biother Radiopharm; 2007 Aug; 22(4):521-30. PubMed ID: 17803447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
